keyword
MENU ▼
Read by QxMD icon Read
search

patient safety diabetes

keyword
https://www.readbyqxmd.com/read/28324484/sodium-glucose-co-transporter-2-sglt2-inhibitor-comparing-trial-data-and-real-world-use
#1
Andrew McGovern, Michael Feher, Neil Munro, Simon de Lusignan
INTRODUCTION: The first cardiovascular safety trial in the sodium-glucose co-transporter-2 (SGLT2) inhibitor drug class, the Empagliflozin Cardiovascular Outcomes and Mortality in Type 2 Diabetes (EMPA-REG OUTCOME) trial, demonstrated significant cardiovascular risk reduction with empagliflozin. It is currently not clear what proportions of people with type 2 diabetes (T2DM) have the same high cardiovascular risk as those included in the trial, and will therefore be likely to experience the same cardiovascular benefit...
March 21, 2017: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/28324049/piloting-a-remission-strategy-in-type-2-diabetes-results-of-a-randomized-controlled-trial
#2
Natalia McInnes, Ada Smith, Rose Otto, Jeffrey Vandermey, Zubin Punthakee, Diana Sherifali, Kumar Balasubramanian, Stephanie Hall, Hertzel C Gerstein
Context: Medical strategies targeting remission of type 2 diabetes have not been systematically studied. Objective: This trial assessed the feasibility, safety and potential to induce remission of a short-term intensive metabolic strategy. Design: A randomized, parallel, open-label pilot trial in 83 participants followed for 52 weeks. Setting: Ambulatory care. Participants: Patients with type 2 diabetes of up to 3 years in duration...
March 15, 2017: Journal of Clinical Endocrinology and Metabolism
https://www.readbyqxmd.com/read/28324038/efficacy-of-exenatide-plus-pioglitazone-versus-basal-bolus-insulin-in-t2dm-patients-with-very-high-hba1c
#3
Muhammad Abdul-Ghani, Osama Mujahid, Ayman Mujahid, Ralph A DeFronzo, Mahmoud Zirie, Amin Jayyousi
Aim: To examine the efficacy and safety of combination therapy with exenatide plus pioglitazone versus basal-bolus insulin in poorly controlled type 2 diabetic patients with very high HbA1c (HbA1c>10%) on metformin plus sulfonylurea and long duration of disease. Research Design and Methods: 101 participants in Qatar Study with very poor glycemic control (HbA1c > 10%) and long duration of diabetes (10.9 years) on maximum/near-maximum doses of sulfonylurea plus metformin were randomized to receive: (i) pioglitazone plus weekly exenatide (Combination Therapy), or (ii) basal plus prandial insulin (Insulin Therapy) to maintain HbA1c <7...
February 1, 2017: Journal of Clinical Endocrinology and Metabolism
https://www.readbyqxmd.com/read/28318520/cardiovascular-safety-of-noninsulin-antidiabetic-drugs-facts-and-promises
#4
A García-Lledó, A M de Santiago-Nocito, F J de Abajo
Non insulin antidiabetic drugs are widely used in patients with type 2 diabetes. However, the drugs' effect in terms of reducing cardiovascular risk has been the subject of controversy. In 2008, based on the evidence of cardiovascular risk resulting from the use of a number of non insulin antidiabetic drugs, the US Food and Drug Administration published directives on the need to perform cardiovascular safety studies. These directives have helped obtain more evidence, such that at present there are 2 families of drugs that can reduce cardiovascular risk...
March 15, 2017: Revista Clínica Española
https://www.readbyqxmd.com/read/28315123/coronary-stents-in-diabetic-patients-state-of-the-knowledge
#5
REVIEW
Pablo Codner, Hitinder Singh Gurm, Apurva Motivala
PURPOSE OF REVIEW: This review article aims to summarize the findings of the most relevant research that compared the use of paclitaxel vs. "limus" based drug eluting stent (DES) in diabetic patients and to define the current state of knowledge with new stent technologies in this patient population. RECENT FINDINGS: Since drug eluting stents (DES) were introduced, it has been of great interest to establish whether paclitaxel or sirolimus eluting stents have the same safety and efficacy features for patients with coronary artery disease...
April 2017: Current Cardiology Reports
https://www.readbyqxmd.com/read/28314656/safety-and-efficacy-of-a-basal-plus-regimen-with-insulin-glargine-and-insulin-glulisine-for-elderly-patients-with-high-cardiovascular-risk-and-type-2-diabetes-mellitus
#6
R Gómez-Huelgas, J Sabán-Ruiz, F J García-Román, N Quintela-Fernández, J M Seguí-Ripoll, M V Bonilla-Hernández, G Romero-Meliá
OBJECTIVES: To assess the safety and efficacy of a basal-plus (BP) regimen with insulin glargine (as basal insulin) and insulin glulisine (as prandial insulin) with the main meal for elderly patients with type 2 diabetes mellitus (DM2) and high cardiovascular risk, following standard clinical practice. PATIENTS AND METHODS: An observational, retrospective study was conducted in 21 centres of internal medicine in Spain. The study included patients aged 65 years or older with DM2, undergoing treatment with a BP regimen for 4 to 12 months before inclusion in the study and a diagnosis of cardiovascular disease or high cardiovascular risk...
March 14, 2017: Revista Clínica Española
https://www.readbyqxmd.com/read/28306636/blood-pressure-lowering-efficacy-and-safety-of-perindopril-indapamide-amlodipine-single-pill-combination-in-patients-with-uncontrolled-essential-hypertension-a-multicenter-randomized-double-blind-controlled-trial
#7
Jean-Jacques Mourad, Celso Amodeo, Martine de Champvallins, Romualda Brzozowska-Villatte, Roland Asmar
OBJECTIVES: This 4-month, double-blind, randomized, controlled trial was designed to demonstrate the superiority of perindopril/indapamide/amlodipine single pill over perindopril/indapamide after 1 month and to determine further up-titration efficacy and safety in patients with mild-to-moderate hypertension. METHODS: After a 1-month run-in period on perindopril/indapamide 5/1.25 mg, patients with SBP/DBP at least 150/95 mmHg and no diabetes or renal insufficiency received perindopril/indapamide/amlodipine 5/1...
March 16, 2017: Journal of Hypertension
https://www.readbyqxmd.com/read/28306165/is-gh-dosing-optimal-in-female-patients-with-adult-onset-gh-deficiency-an-analysis-from-the-nordinet-%C3%A2-international-outcome-study
#8
Charlotte Höybye, Matthias M Weber, Effie Pournara, Birgitte Tønnes Pedersen, Beverly M K Biller
OBJECTIVE: To evaluate gender differences in GH dosing, IGF-I and cardiovascular risk markers in adults with GH deficiency (GHD). DESIGN: NordiNet(®) International Outcome Study (NCT00960128), a non-interventional, multicentre study, evaluates the long-term effectiveness and safety of Norditropin(®) (Novo Nordisk A/S) in the real-life clinical setting. PATIENTS: Non-diabetic patients (n=252; 41.7% female) with adult-onset GHD (age ≥20 years at GH start), ≥4 years' GH therapy, and glycosylated haemoglobin (HbA1c ) data at baseline and 4 years...
March 17, 2017: Clinical Endocrinology
https://www.readbyqxmd.com/read/28303724/non-alcoholic-fatty-liver-disease-nafld-pathogenesis-classification-and-effect-on-drug-metabolizing-enzymes-and-transporters
#9
Enoch Cobbina, Fatemeh Akhlaghi
Non-alcoholic fatty liver disease (NAFLD) is a spectrum of liver disorders. It is defined by the presence of steatosis in more than 5% of hepatocytes with little or no alcohol consumption. Insulin resistance, the metabolic syndrome or type 2 diabetes and genetic variants of PNPLA3 or TM6SF2 seem to play a role in the pathogenesis of NAFLD. The pathological progression of NAFLD follows tentatively a "three-hit" process namely steatosis, lipotoxicity and inflammation. The presence of steatosis, oxidative stress and inflammatory mediators like TNF-α and IL-6 has been implicated in the alterations of nuclear factors such as CAR, PXR, PPAR-α in NAFLD...
March 17, 2017: Drug Metabolism Reviews
https://www.readbyqxmd.com/read/28303721/effectiveness-and-safety-of-vildagliptin-and-vildagliptin-add-on-to-metformin-in-real-world-settings-in-egypt-results-from-the-guard-study
#10
Salah Shelbaya, Sameh Rakha
OBJECTIVE: The GUARD study evaluated the effectiveness, safety, and tolerability of vildagliptin treatment with or without metformin in patients with type 2 diabetes mellitus (T2DM) in real-life settings. Here we present the results of the GUARD study for the patient subset from Egypt. RESEARCH DESIGN AND METHODS: This was a 24 ± 6 weeks, prospective, non-interventional study that enrolled adult patients with T2DM receiving vildagliptin or vildagliptin + metformin combination therapy as per local prescribing information...
March 17, 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/28303626/lixisenatide-as-add-on-treatment-among-patients-with-different-%C3%AE-cell-function-levels-as-assessed-by-homa-%C3%AE-index
#11
Riccardo C Bonadonna, Lawrence Blonde, Mikhail Antsiferov, Rachele Berria, Pierre Gourdy, Mensud Hatunic, Viswanathan Mohan, Michael Horowitz
BACKGROUND: The effect of lixisenatide - a prandial once-daily glucagon-like peptide-1 receptor agonist - on glycaemic control in patients with inadequately controlled type 2 diabetes (T2DM), stratified by baseline β-cell function was assessed. METHODS: The 24-week GetGoal-M, -P and -S trials evaluated the efficacy and safety of lixisenatide in combination with oral antidiabetic agents. This post hoc analysis used data from patients receiving lixisenatide in these trials, divided into matched cohorts by propensity scoring and stratified according to baseline homeostasis model assessment of β-cell function (HOMA-β) index levels (high HOMA-β: > median HOMA-β [28...
March 17, 2017: Diabetes/metabolism Research and Reviews
https://www.readbyqxmd.com/read/28302958/efficacy-and-safety-analyses-across-4-subgroups-combining-low-and-high-age-and-body-mass-index-groups-in-japanese-phase-3-studies-of-dulaglutide-0-75-mg-after-26-weeks-of-treatment
#12
Kumiko Hamano, Hiroshi Nishiyama, Akiko Matsui, Manaka Sato, Masakazu Takeuchi
In 855 Japanese patients with type 2 diabetes receiving once weekly dulaglutide 0.75 mg in 3 phase 3 studies, the effects on efficacy and safety at week 26 (last observation carried forward) were investigated in a post hoc descriptive analysis of subgroups of age (<65 years [young], ≥65 years [elderly]) and body mass index (BMI [<25 kg/m(2), ≥25 kg/m(2)]). The 4 subgroups were as follows: 1) the young/low-BMI subgroup (Y/L) (n = 255); 2) the young/high-BMI subgroup (Y/H) (n = 386), 3) the elderly/low-BMI subgroup (E/L) (n = 137), and 4) the elderly/high-BMI subgroup (E/H) (n = 77)...
March 7, 2017: Endocrine Journal
https://www.readbyqxmd.com/read/28302923/improving-medication-safety-and-diabetes-management-in-hong-kong-a-multidisciplinary-approach
#13
A Ys Chung, S Anand, I Ck Wong, K Cb Tan, C Ff Wong, W Cm Chui, E W Chan
INTRODUCTION: Patients with diabetes often require complex medication regimens. The positive impact of pharmacists on improving diabetes management or its co-morbidities has been recognised worldwide. This study aimed to characterise drug-related problems among diabetic patients in Hong Kong and their clinical significance, and to explore the role of pharmacists in the multidisciplinary diabetes management team by evaluating the outcome of their clinical interventions. METHODS: An observational study was conducted at the Diabetes Clinic of a public hospital in Hong Kong from October 2012 to March 2014...
March 17, 2017: Hong Kong Medical Journal, Xianggang Yi Xue za Zhi
https://www.readbyqxmd.com/read/28302466/bioflow-iii-satellite-one-year-clinical-outcomes-of-diabetic-patients-treated-with-a-biodegradable-polymer-sirolimus-eluting-stent-and-comprehensive-medical-surveillance
#14
Ran Kornowski, Ariel Roguin, Haim Danenberg, Hana Vaknin Assa, Eitan Abergel, Eliezer Rozenbaum, Victor Guetta, Uri Landes, Refat Jabara, Amnon Merdler, Amit Segev, Morris Mosseri, Abid Assali
BACKGROUND: Drug-eluting stents with biodegradable polymer might be particularly useful in diabetic patients who are at increased risk for target lesion/target vessel revascularization. We therefore aimed at assessing the safety and performance of a biodegradable polymer sirolimus-eluting stent (BP-SES) in combination with comprehensive optimal medical therapy following coronary interventions. METHODS: This prospective, multicenter registry was conducted at six centers in Israel...
February 21, 2017: Cardiovascular Revascularization Medicine: Including Molecular Interventions
https://www.readbyqxmd.com/read/28300430/calculated-daily-insulin-dosages-overestimate-prescribed-insulin-doses-in-type-2-diabetes
#15
Karel Kostev, Wolfgang Rathmann
BACKGROUND: The aim was to compare the prescribed and calculated daily insulin dosages based on prescription data in type 2 diabetes patients in a general practice database. METHODS: A total of 17 782 type 2 diabetes patients (age: 70.0 ± 11.5 years; 52% males; 16% diabetologist care) with ≥2 insulin prescriptions from 834 practices were analyzed (Disease Analyser: 01/2011-12/2015). Prescribed daily dosage (PDD) (physician documentation) and calculated daily dose (CDD) (pack size × strength × volume / days between 2 prescriptions) were calculated for short-acting, long-acting, and premixed insulins...
October 1, 2016: Journal of Diabetes Science and Technology
https://www.readbyqxmd.com/read/28296349/dipeptidyl-peptidase-4-inhibitors-as-preferable-oral-hypoglycemic-agents-in-terms-of-treatment-satisfaction-results-from-a-multicenter-12-week-open-label-randomized-controlled-study-in-japan
#16
Hitoshi Ishii, Yasuaki Hayashino, Yasuhiro Akai, Matahiro Yabuta, Satoru Tsujii
AIMS/INTRODUCTION: To compare the treatment satisfaction of four classes of oral hypoglycemic agents (OHAs): dipeptidyl peptidase-4 (DPP-4) inhibitors, α-glucosidase inhibitors (αGI), biguanides (BG), and sulfonylureas (SU), which are common initial treatments for type 2 diabetes mellitus patients in Japan, and to identify the best OHA in terms of treatment satisfaction. MATERIALS AND METHODS: In this 12-week, randomized, controlled, open-label study, Japanese outpatients with type 2 diabetes mellitus who were naïve to pharmacological treatment were randomly assigned a DPP-4 inhibitor, a BG, an αGI, or a SU...
March 14, 2017: Journal of Diabetes Investigation
https://www.readbyqxmd.com/read/28296239/stent-placement-in-the-superficial-femoral-and-proximal-popliteal-arteries-with-the-innova-self-expanding-bare-metal-stent-system
#17
Richard J Powell, Michael R Jaff, Herman Schroë, Andrew Benko, Juan Diaz-Cartelle, Stefan Müller-Hülsbeck
OBJECTIVES: The SuperNOVA trial was designed to evaluate performance of the Innova Vascular Self-Expanding Stent System (Boston Scientific, Marlborough, MA) for treating lesions in the femoropopliteal arteries. METHODS: Patients with chronic lower limb peripheral artery disease (Rutherford category 2, 3, or 4) and atherosclerotic lesions in the native superficial femoral and/or proximal popliteal artery (lengths 30-190 mm) were enrolled in this single-arm, multinational study...
March 15, 2017: Catheterization and Cardiovascular Interventions
https://www.readbyqxmd.com/read/28296055/efficacy-and-safety-of-saxagliptin-compared-with-acarbose-in-chinese-patients-with-type-2-diabetes-mellitus-uncontrolled-on-metformin-monotherapy-results-of-a-phase-iv-open-label-randomized-controlled-study-the-smart-study
#18
Jin Du, Li Liang, Hui Fang, Fengmei Xu, Wei Li, Liya Shen, Xueying Wang, Chun Xu, Fang Bian, Yiming Mu
AIM: To investigate the efficacy, safety and tolerability of saxagliptin compared with acarbose in Chinese patients with type 2 diabetes mellitus (T2DM) inadequately controlled with metformin monotherapy. MATERIALS AND METHODS: SMART was a 24-week, multicentre, randomized, parallel-group, open-label Phase IV study conducted at 35 sites in China (24/09/2014-29/09/2015). The primary outcome was change from baseline in HbA1c at Week 24. Secondary efficacy outcomes assessed at Week 24 included the proportion of patients achieving HbA1c<7...
March 14, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/28294702/safety-and-efficacy-of-a-glucagon-like-peptide-1-receptor-agonist-added-to-basal-insulin-therapy-versus-basal-insulin-with-or-without-a-rapid-acting-insulin-in-patients-with-type-2-diabetes-results-of-a-meta-analysis
#19
Carol H Wysham, Jay Lin, Louis Kuritzky
OBJECTIVE: To consolidate the evidence from randomized controlled trials evaluating the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) as add-on to basal insulin therapy in type 2 diabetes (T2D) patients. RESEARCH DESIGN AND METHODS: We searched the EMBASE® and NCBI PubMed (Medline) databases and relevant congress abstracts for randomized controlled trials evaluating the efficacy and safety of GLP-1 RAs as add-on to basal insulin compared with basal insulin with or without rapid-acting insulin (RAI) through 23 May 2016...
March 15, 2017: Postgraduate Medicine
https://www.readbyqxmd.com/read/28294488/the-efficacy-and-safety-of-sitagliptin-as-compared-with-glimepiride-in-japanese-patients-aged-60-years-or-older-with-type-2-diabetes-mellitus-start-j-trial
#20
Yasuo Terauchi, Yuichiro Yamada, Hitoshi Ishida, Mitsuru Ohsugi, Masafumi Kitaoka, Jo Satoh, Daisuke Yabe, Nobuyuki Shihara, Yutaka Seino
Non structured abstract To evaluate the efficacy and safety of sitagliptin administered to elderly patients with type 2 diabetes mellitus (T2DM) for one year as compared with glimepiride. Patients aged ≥ 60 years with T2DM and inadequately controlled blood glucose were randomly assigned to sitagliptin 50 mg qd or glimepiride 0.5 mg qd for 52 weeks. The primary efficacy endpoint was the change in HbA1c from baseline to Week 52. Secondary efficacy endpoints included self-monitored blood glucose (SMBG) and weight...
March 9, 2017: Diabetes, Obesity & Metabolism
keyword
keyword
105285
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"